ALB and metabolic syndrome: Microalbuminuria, defined as urinary albumin excretion of 20-200 mg/L [1], is an early marker of chronic kidney disease (CKD) and is also associated with the increased risk of cardiovascular disease, all-cause mortality, and metabolic disorders, including type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) [2–5].